Professor Deborah Marsh is a cancer cell and molecular biologist skilled in genetics and epigenetics. She was awarded her PhD from the University of Sydney and undertook postdoctoral studies with the late Professor Charis Eng at the Dana Farber Cancer Institute associated with Harvard Medical School, Boston, USA (1996-1999). Here, she was involved in implicating the tumour suppressor gene PTEN in a range of familial and sporadic cancers. Today, PTEN is well recognised as the second most frequently mutated gene in human malignancy. After returning to Australia she established her research group at the Kolling Institute associated with the University of Sydney (1999-2018), before moving to the University of Technology Sydney (UTS) to lead the Translational Oncology Group and serve as the Discipline Leader of Medical Science. She has a broad interest in cancers that affect women with a specific focus on ovarian cancer and a growing interest in endometriosis that is associated with ovarian cancer. Her group works in gene editing and advanced 3D cell culture modelling. They have specific interests in drug repurposing and the intersection of genetics and epigenetics that models the chromatin landscape, affecting chromatin remodelling complexes such as SWI/SNF (SWItch/Sucrose Non-Fermentable). Prof Marsh has published more than 145 papers with over 12,800 citations. She was the inaugural recipient of the NSW Premier’s Award for Outstanding Cancer Research Fellow and a previous NSW Young Tall Poppy.